Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (ESP2011-002)

This study has been completed.
Information provided by (Responsible Party):
Esperance Pharmaceuticals Inc Identifier:
First received: December 2, 2011
Last updated: June 9, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)